Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
El Paso healthcare providers explore Vivitrol as a less known addiction treatment
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a regimen that works.
Alkermes upgraded to Buy from Hold at Stifel
Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...
ETF Daily News11d
Alkermes (NASDAQ:ALKS) Rating Reiterated by Piper Sandler
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
Nasdaq14d
Alkermes's Earnings: A Preview
Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect
Alkermes PLC (NASDAQ:ALKS) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue ...
Alkermes (NASDAQ:ALKS) Given New $43.00 Price Target at Cantor Fitzgerald
Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...
Wall Street Journal3d
Alkermes PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...